4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced a change in major shareholdings.
4basebio
940.00GBX
-4.57%
Market Cap
145.44M
Volume
3
0% of avg
P/E Ratio
-0.16
EPS (TTM)
-60
Beta
1.03
Day Range
940.00p - 940.00p
52 Week Range
940.00p940.00p1,600.00p
940.00p
Upcoming Events
4BB
NEUTRAL4basebio PLC Announces Major Shareholder Disclosure
The biotechnology company has received a notification of a change in major shareholder holdings.
4BB
NEUTRAL4basebio PLC Reports Doubled DNA Revenues but Widening Losses in 2024 Results
The biotechnology firm doubled its DNA revenues but reported widening losses. Despite securing significant funding and expanding its customer base, the company expects to remain loss-making in 2025.
4BB
NEUTRAL4basebio CEO Increases Stake
The CEO of the biotechnology company has purchased additional shares in the business on behalf of his children.
4BB
GOOD4basebio Receives GMP Licence for UK Manufacturing Facility
The biotechnology company has received a key regulatory certification for its UK manufacturing facility, strengthening its position in advanced therapeutics.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
4BB
NEUTRAL4basebio PLC announces RBC Capital Markets initiates research coverage
The biotechnology company announces that RBC Capital Markets has initiated research coverage.
4BB
NEUTRAL4basebio PLC Announces Employee Share Incentive Plan
The biotechnology company has announced an employee share incentive plan, issuing new shares to be held in trust for eligible employees.
4BB
NEUTRAL4basebio COO Increases Shareholding
The biotechnology company's COO has acquired additional shares, increasing her stake in the business.
4BB
GOOD4basebio Appoints New Chief Commercial Officer to Drive Growth
Biotechnology company 4basebio appoints new Chief Commercial Officer to drive growth in synthetic DNA solutions.